Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10416127" target="_blank" >RIV/00216208:11110/20:10416127 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00023728:_____/20:N0000034

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=m-X0PqQvaJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=m-X0PqQvaJ</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1093/rheumatology/kez656" target="_blank" >10.1093/rheumatology/kez656</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

  • Popis výsledku v původním jazyce

    Objectives. To assess the impact of &apos;patient&apos;s minus evaluator&apos;s global assessment of disease activity&apos; (Delta PEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods. Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Research Collaboration Network were pooled. Retention rates were compared by Kaplan-Meier analyses with log-rank test and by Cox regression, and remission rates by chi(2) test and by logistic regression across quartiles of baseline Delta PEG, separately in female and male PsA and axSpA patients. Results. We included 14 868 spondyloarthritis (5855 PsA, 9013 axSpA) patients. Baseline Delta PEG was negatively associated with 6/12/24-months&apos; TNFi retention rates in female and male PsA and axSpA patients (P &lt; 0.001), with 6/12/24-months&apos; BASDAI &lt; 2 (P &lt;= 0.002) and ASDAS &lt; 1.3 (P &lt;= 0.005) in axSpA patients, and with DAS28CRP(4)&lt;2.6 (P &lt;= 0.04) and DAPSA28 &lt;= 4 (P &lt;= 0.01), but not DAS28CRP(3)&lt;2.6 (P &gt;= 0.13) in PsA patients, with few exceptions on remission rates. Retention and remission rates were overall lower in female than male patients. Conclusion. High baseline patient&apos;s compared with evaluator&apos;s global assessment was associated with lower 6/12/24-months&apos; remission as well as retention rates of first TNFi in both PsA and axSpA patients. These results highlight the importance of discordance between patient&apos;s and evaluator&apos;s perspective on disease outcomes.

  • Název v anglickém jazyce

    Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

  • Popis výsledku anglicky

    Objectives. To assess the impact of &apos;patient&apos;s minus evaluator&apos;s global assessment of disease activity&apos; (Delta PEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods. Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Research Collaboration Network were pooled. Retention rates were compared by Kaplan-Meier analyses with log-rank test and by Cox regression, and remission rates by chi(2) test and by logistic regression across quartiles of baseline Delta PEG, separately in female and male PsA and axSpA patients. Results. We included 14 868 spondyloarthritis (5855 PsA, 9013 axSpA) patients. Baseline Delta PEG was negatively associated with 6/12/24-months&apos; TNFi retention rates in female and male PsA and axSpA patients (P &lt; 0.001), with 6/12/24-months&apos; BASDAI &lt; 2 (P &lt;= 0.002) and ASDAS &lt; 1.3 (P &lt;= 0.005) in axSpA patients, and with DAS28CRP(4)&lt;2.6 (P &lt;= 0.04) and DAPSA28 &lt;= 4 (P &lt;= 0.01), but not DAS28CRP(3)&lt;2.6 (P &gt;= 0.13) in PsA patients, with few exceptions on remission rates. Retention and remission rates were overall lower in female than male patients. Conclusion. High baseline patient&apos;s compared with evaluator&apos;s global assessment was associated with lower 6/12/24-months&apos; remission as well as retention rates of first TNFi in both PsA and axSpA patients. These results highlight the importance of discordance between patient&apos;s and evaluator&apos;s perspective on disease outcomes.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30226 - Rheumatology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Ostatní

  • Rok uplatnění

    2020

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Rheumatology

  • ISSN

    1462-0324

  • e-ISSN

  • Svazek periodika

    59

  • Číslo periodika v rámci svazku

    9

  • Stát vydavatele periodika

    GB - Spojené království Velké Británie a Severního Irska

  • Počet stran výsledku

    7

  • Strana od-do

    2455-2461

  • Kód UT WoS článku

    000574394600043

  • EID výsledku v databázi Scopus

    2-s2.0-85090080184